SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Q1 FY26: Revenue ₹196.05 Cr, PAT ₹20.50 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on SMS Pharmaceuticals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY26 revenue from operations: ₹196.05 crore - Year-on-year (YoY) revenue growth: 19% (Q1FY26 vs Q1FY25) - Quarterly revenue trend: from ₹164.45 crore in Q1FY25 to ₹196.05 crore in Q1FY26 - Vol EBITDA for Q1FY26: ₹39.37 crore, up 17% YoY - EBITDA Margin: 20%, stable YoY (Q1FY26 vs Q1FY25) - Profit After Tax (PAT) for Q1FY26: ₹20.50 crore (after minority interest and associate s
From SMS Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1FY26 revenue from operations: ₹196.05 crore
- Year-on-year (YoY) revenue growth: 19% (Q1FY26 vs Q1FY25)
- Quarterly revenue trend: from ₹164.45 crore in Q1FY25 to ₹196.05 crore in Q1FY26
- Volume growth is cited as a driver for the strong start in FY26 (Page 4)
2 more points management made on revenue & sales performance
Profitability & Margins
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New Capex plan of ₹250 crore approved for existing and new products, R&D facility, and CMO business (Page 16).
- Capacity expansion aiming to achieve a production target of 1,000 MT per month (Page 16).
- Started commercial production of key intermediates; gross margin impact expected in Q2FY26 (Page 4).
- ₹250 crore Capex plan is on track as of Q1FY26 (Page 4).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q1 FY26 results?
Q1FY26 revenue from operations: ₹196.05 crore - Year-on-year (YoY) revenue growth: 19% (Q1FY26 vs Q1FY25) - Quarterly revenue trend: from ₹164.45 crore in Q1FY25 to ₹196.05 crore in Q1FY26 - Vol EBITDA for Q1FY26: ₹39.37 crore, up 17% YoY - EBITDA Margin: 20%, stable YoY (Q1FY26 vs Q1FY25) - Profit After Tax (PAT) for Q1FY26: ₹20.50 crore (after minority interest and associate s
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
New Capex plan of ₹250 crore approved for existing and new products, R&D facility, and CMO business (Page 16).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.